Clinical Trial Update: A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate CT1194D in relapsed/refractory B-cell neoplasms. The trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Neoplasms

Drugs mentioned

• CT1194D

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory B-Cell Neoplasms | Phase 1 | Status: NOT_YET_RECRUITING